TITLE

The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort

AUTHOR(S)

Altmann, Mathias; an der Heiden, Matthias; Scheufele, Ramona; Hartmann, Katrin; Houareau, Claudia; Bartmeyer, Barbara; Hamouda, Osamah

PUB. DATE

January 2012

SOURCE

BMC Infectious Diseases;2012, Vol. 12 Issue 1, p94

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: With ageing of the HIV-infected population, long-term exposure to treatment, varying adherence, emerging resistance and complications to therapies, effectiveness of Highly Active Antiretroviral Therapy (HAART) needs to be monitored continuously at the population level. The German HIV-1 Seroconverter Cohort is a multi-centre, open, long-term observational cohort including patients with a known or reliably estimated date of HIV-infection -i.e. last negative and first positive HIV antibody test within a maximum three-year interval or laboratory evidence of seroconversion. Our study aims to investigate survival improvements and changes in AIDS risk over calendar periods in the German HIV-1 Seroconverter Cohort. Methods: Retrospective (for the pre-1997 period) and prospective (since 1997) data from the German HIV-1 Seroconverter Cohort were used. Time from seroconversion to first AIDS-defining event over calendar periods was analysed by using Cox models adjusting for age at seroconversion, sex, transmission groups and short HIV test interval. Kaplan-Meier methods were used to determine expected survival (remaining AIDS-free) by calendar period. Results: 2162 seroconverters with 8976 person-years of observation were included in our analysis (up to 31.12.2010). A total of 196 first AIDS-defining events were reported. Two periods -i.e. 1997-2000 and 2007-2010- were statistically associated with a reduction in the risk of AIDS, accounting for an overall reduction of 80%. Compared to1997-2000, hazard ratios were 2.6 (95%CI, 1.6-4.8; p = 0.000) in pre-1997 and 0.5 (95%CI, 0.3-0.8; p = 0.007) in 2007-2010. Independent risk factor for AIDS progression was age at seroconversion (HR, 1.3 per 10 year-increase; p = 0.001). Conclusion: HAART effectiveness has improved in the German HIV-1-Seroconverter Cohort. The risk to develop AIDS decreased significantly in 1997-2000 and in 2007-2010. However, elderly may require particular monitoring in view of their faster progression to AIDS.

ACCESSION #

84227420

 

Related Articles

• Patient Adherence To HAART Regimens: Challenges For Physician Assistants And Health Care Providers. Day, Marvin // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p42 

  Patients often adhere incompletely and inadequately to highly active antiretroviral therapy (HAART) regimens used in the treatment of HIV infection. This permits the emergence of HIV variants that are resistant to current treatment. The physician assistant often assumes the responsibility for...

• Characterization of Antibodies to Human Immunodeficiency Viral Proteins in the Sera of HIV Infected and Non HIV Infected HBsAg Seropositive Patients. Olaniyan, Mathew Folaranmi // Global Journal of Health Science;Apr2010, Vol. 2 Issue 1, p193 

  This work was designed to characterize the HIV viral antibodies in HIV infected and non-HIV infected HBsAg seropositive patients. Fifty non HIV infected (male = 25; female = 25)and 50 HIV infected HBsAg seropositive patients (male - n = 25; female - n = 25) aged 6 - 64 years recruited from the...

• The Safety and Efficacy of Enfuvirtide Therapy for HIV Infection in Patients with Hemophilia: A Case Series. Polizzotto, Mark N.; Street, Alison M.; Wright, Edwina // Clinical Infectious Diseases;8/15/2007, Vol. 45 Issue 4, pe39 

  The treatment of patients with human immmunodeficiency virus (HIV) infection and hemophilia involves unique challenges that may be addressed with novel antiretroviral classes. We describe the safety and efficacy of enfuvirtide therapy in 4 patients with severe hemophilia A. Although local skin...

• Oral Glucose Loading for Detection of Mitochondrial Toxicity During HAART in HIV-Infected Patients. Ter Hofstede, Hadewych J. M.; Borm, George F.; Koopmans, Peter P. // Current HIV Research;Oct2007, Vol. 5 Issue 4, p389 

  Nucleoside reverse transcriptase inhibitors used in antiretroviral therapy may cause mitochondrial toxicity. Mitochondrial dysfunction leads to disturbance of the glucose metabolism, resulting in an accumulation of L-lactate. We tested the hypothesis that an oral glucose tolerance test (OGTT)...

• Impact of Indinavir on the Quality of Life in Patients with Advanced HIV Infection Treated with Zidovudine and Lamivudine. Coplan, Paul M.; Cook, John R.; Carides, George W.; Heyse, Joseph F.; Wu, Albert W.; Hammer, Scott M.; Nguyen, Bach-Yen; Meibohm, Anne R.; DiNubile, Mark J. // Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p426 

  Objective. in AIDS Clinical Trial Group (ACTG) study 320, triple-combination antiretroviral therapy including indinavir significantly slowed progression to acquired immunodeficiency syndrome or death, compared with treatment with dual nucleoside reverse-transcriptase inhibitors (NRTIs) alone, in...

• Five-Year Outcomes of the China National Free Antiretroviral Treatment Program.  // Annals of Internal Medicine;8/18/2009, Vol. 151 Issue 4, pI-42 

  The article presents a study on the rate of recovery of patients in the National Free Antiretroviral Treatment Program in China after five years. It notes that 48,785 patients with HIV were enrolled in the program under the highly active antiretroviral therapy. It mentions that after 6 months of...

• Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial. Cahn, Pedro; Villacian, Jorge; Lazzarin, Adriano; Katlama, Christine; Grinsztejn, Beatriz; Arasteh, Keikawus; López, Paulo; Clumeck, Nathan; Gerstoft, Jan; Stavrianeas, Nikolas; Moreno, Santiago; Antunes, Francisco; Neubacher, Dietmar; Mayers, Douglas // Clinical Infectious Diseases;11/15/2006, Vol. 43 Issue 10, p1347 

  Background. Tipranavir, a novel protease inhibitor, has demonstrated antiviral activity against protease inhibitor- resistant human immunodeficiency virus type 1 (HIV-1) isolates. The Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST-2)...

• Factors Affecting Adherence to Antiretroviral Therapy. Chesney, Margaret A. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS171 

  Enumerates the factors that influence adherence to antiretroviral therapy for treating HIV infections. Patient factors; Medication regimen; Patient-health care provider relationship; System of care; Reasons reported by HIV-infected individuals for not taking their medications.

• Abnormal Cytokine Production by Circulating Monocytes and Dendritic Cells of Myeloid Origin in ART-Treated HIV-1+ Patients Relates to CD4+ T-Cell Recovery and HCV Co-Infection. Almeida, Maria; Cordero, Miguel; Almeida, Julia; Orfao, Alberto // Current HIV Research;Jul2007, Vol. 5 Issue 3, p325 

  HIV-1 infection is associated with dysregulation of cytokine production by peripheral blood (PB) monocytes and dendritic cells (DC), but controversial results have been reported. We aimed to analyze the effect of antiretroviral therapy (ART) on the in vitro production of inflammatory cytokines...

Read the Article